These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 2180661)

  • 21. Implications and results of the Diabetes Control and Complications Trial.
    Tamborlane WV; Ahern J
    Pediatr Clin North Am; 1997 Apr; 44(2):285-300. PubMed ID: 9130921
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Issues surrounding tight glycemic control in people with type 2 diabetes mellitus.
    Cerveny JD; Leder RD; Weart CW
    Ann Pharmacother; 1998 Sep; 32(9):896-905. PubMed ID: 9762378
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Results of the DCCT trial. Implications for managing our patients with diabetes.
    Worrall G
    Can Fam Physician; 1994 Nov; 40():1955-60, 1963-5. PubMed ID: 7841827
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Diabetes Control and Complications Trial (DCCT). A milestone in diabetes management.
    Chrisholm DJ
    Med J Aust; 1993 Dec 6-20; 159(11-12):721-3. PubMed ID: 8264454
    [No Abstract]   [Full Text] [Related]  

  • 25. How have patients reacted to the implications of the DCCT?
    Thompson CJ; Cummings JF; Chalmers J; Gould C; Newton RW
    Diabetes Care; 1996 Aug; 19(8):876-9. PubMed ID: 8842607
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Deleterious effects of increased body weight associated with intensive insulin therapy for type 1 diabetes: increased blood pressure and worsened lipid profile partially negate improvements in life expectancy.
    Palmer AJ; Roze S; Valentine WJ; Minshall ME; Lammert M; Nicklasson L; Spinas GA
    Curr Med Res Opin; 2004 Aug; 20 Suppl 1():S67-73. PubMed ID: 15324518
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metabolic memory: Evolving concepts.
    Misra A; Bloomgarden Z
    J Diabetes; 2018 Mar; 10(3):186-187. PubMed ID: 29091343
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Implementation of a multicomponent process to obtain informed consent in the Diabetes Control and Complications Trial. The DCCT Research Group.
    Control Clin Trials; 1989 Mar; 10(1):83-96. PubMed ID: 2467781
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glycemic control and complications of diabetes mellitus: practical implications of the Diabetes Control and Complications Trial (DCCT).
    Hoogwerf BJ; Brouhard BH
    Cleve Clin J Med; 1994; 61(1):34-7; quiz 80-2. PubMed ID: 8124845
    [No Abstract]   [Full Text] [Related]  

  • 30. Hypoglycemia in type 1 diabetes: a still unresolved problem in the era of insulin analogs and pump therapy.
    Shalitin S; Phillip M
    Diabetes Care; 2008 Feb; 31 Suppl 2():S121-4. PubMed ID: 18227471
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expanded role of the dietitian in the Diabetes Control and Complications Trial: implications for clinical practice. The DCCT Research Group.
    Delahanty L; Simkins SW; Camelon K
    J Am Diet Assoc; 1993 Jul; 93(7):758-64, 767. PubMed ID: 8320401
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Resource utilization and costs of care in the diabetes control and complications trial.
    Diabetes Care; 1995 Nov; 18(11):1468-78. PubMed ID: 8722072
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Clinical study of the month. After DCCT, the EDIC study].
    Scheen AJ
    Rev Med Liege; 2000 Mar; 55(3):187-9. PubMed ID: 10823011
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The impact of the Trial Coordinator in the Diabetes Control and Complications Trial (DCCT). The DCCT Research Group.
    Ahern J; Grove N; Strand T; Wesche J; Seibert C; Brenneman AT; Tamborlane WV
    Diabetes Educ; 1993; 19(6):509-12. PubMed ID: 8156864
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intensive Diabetes Treatment and Cardiovascular Outcomes in Type 1 Diabetes Mellitus: Implications of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study 30-Year Follow-up.
    Subramanian S; Hirsch IB
    Endocrinol Metab Clin North Am; 2018 Mar; 47(1):65-79. PubMed ID: 29407057
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of intensive glycemic control on levels of markers of inflammation in type 1 diabetes mellitus in the diabetes control and complications trial.
    Schaumberg DA; Glynn RJ; Jenkins AJ; Lyons TJ; Rifai N; Manson JE; Ridker PM; Nathan DM
    Circulation; 2005 May; 111(19):2446-53. PubMed ID: 15867184
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Implications of the diabetes control and complications trial. American Diabetes Association.
    J Fla Med Assoc; 1998 Aug; 85(2):22-4. PubMed ID: 9782715
    [No Abstract]   [Full Text] [Related]  

  • 38. Weight gain trajectories and obesity rates in intensive and conventional treatments of type 1 diabetes from the DCCT compared with a control population without diabetes.
    Carlson NE; Horton KW; Hokanson JE; Cleary PA; Jacobs DR; Brunzell JD; Purnell JQ;
    Diabet Med; 2022 May; 39(5):e14794. PubMed ID: 35040196
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reliability and validity of a diabetes quality-of-life measure for the diabetes control and complications trial (DCCT). The DCCT Research Group.
    Diabetes Care; 1988 Oct; 11(9):725-32. PubMed ID: 3066604
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Update on major trials for the prevention of type 1 diabetes mellitus: the American Diabetes Prevention Trial (DPT-1) and the European Nicotinamide Diabetes Intervention Trial (ENDIT).
    Schatz DA; Bingley PJ
    J Pediatr Endocrinol Metab; 2001; 14 Suppl 1():619-22. PubMed ID: 11393553
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.